A significant percentage of adolescent athletes have an Attention-Deficit/Hyperactivity Disorder (ADHD) diagnosis and a prescription for stimulant medication (Adderall, Vyvanse, Concerta, Ritalin, others). The medications work clinically and are part of how many of these kids manage school and life.
At the competitive level, these same medications are banned by most anti-doping organizations without specific paperwork in place. The Therapeutic Use Exemption (TUE) process is the protection.
Most families with ADHD-diagnosed kids do not encounter this until the kid is being recruited or starts competing at a level where testing happens. Encountering it for the first time during testing is the worst time to learn about it.
This piece is the framework.
The banned-substance reality.
ADHD stimulant medications are banned by:
The World Anti-Doping Agency (WADA) Prohibited List.
The U.S. Anti-Doping Agency (USADA), which administers WADA-aligned testing for U.S. Olympic-track athletes.
The National Collegiate Athletic Association (NCAA), which tests college athletes.
The International Olympic Committee (IOC) for Olympic competition.
Most state-level high school athletic associations that test (a minority of states).
The reasoning: stimulants can enhance performance through improved focus, reduced fatigue perception, and increased alertness. This is true regardless of whether the athlete has ADHD; the medication works similarly in athletes with and without the diagnosis.
Without specific paperwork, an athlete tested positive for prescribed ADHD medication can face the same consequences as deliberate doping.
The Therapeutic Use Exemption (TUE) process.
The TUE is the formal exemption that allows an athlete with a legitimate medical need for a banned substance to use it without violating anti-doping rules.
For ADHD medication specifically, the TUE process typically requires:
Documented ADHD diagnosis from a qualified clinician (psychiatrist, pediatrician with ADHD evaluation expertise, or psychologist with prescribing privileges in some states).
The clinical evaluation supporting the diagnosis (history, observation, validated screening tools, sometimes psychological testing).
The prescribing physician’s documentation supporting the medication choice and dose.
Documentation that non-banned alternatives have been tried or considered (some TUE applications require this).
For USADA-tested athletes, the TUE application is submitted through USADA’s online portal. For NCAA athletes, the TUE is handled through the athletic department’s compliance office.
The high-school transition.
For high-school athletes being recruited, the TUE process should begin before the athlete arrives at college. The compliance officer at the college will typically initiate or transfer the documentation.
Some state high-school athletic associations also have TUE-like processes for state-level testing. The minority of states that test high-schoolers vary in their procedures.
For families with a recruited ADHD-diagnosed kid, the conversation with the college compliance office before enrollment matters.
The timing question.
TUE applications can take weeks to months for approval. Submitting just before competition is not a guarantee of timely processing.
For families with kids in the recruiting pipeline:
Initiate the TUE process during junior year of high school, before college enrollment.
Maintain the documentation in the family’s records. The school athletic department may need it, the college may need it, future levels (Olympic, professional) may need it.
Update the documentation as medication changes occur. A kid switching from Adderall to Vyvanse needs the change documented in the TUE file.
The diagnostic-quality question.
The TUE process examines the underlying diagnosis. ADHD diagnoses based on cursory screening, without formal evaluation, sometimes fail the TUE review. The athlete with a strong evaluation history has an easier TUE approval than the athlete with a sketchy diagnosis.
For families: if your kid’s ADHD diagnosis is recent or based on minimal evaluation, formal evaluation by a qualified clinician (typically a psychiatrist or psychologist with ADHD specialization) strengthens both the clinical care and the eventual TUE.
The AAP’s diagnostic standards for pediatric ADHD include:
Clinical interview with the patient and family.
Validated rating scales (Vanderbilt, Conners).
Information from multiple settings (home, school).
Consideration of alternative diagnoses (anxiety, depression, learning disabilities can present similarly).
Sometimes psychological or neuropsychological testing.
A diagnosis based on the AAP-aligned evaluation framework is robust. A diagnosis based on a 15-minute screen at a primary-care visit may be challenged.
The clinical question for athletes.
The ADHD-medication decision is primarily clinical, not athletic. The kid needs the medication to function in school and daily life or does not.
For some athletes, ADHD medication produces measurable improvement in academic performance and life functioning. For some, it does not. The benefit is individual.
For some athletes, the medication’s side effects (appetite suppression, sleep disruption, cardiovascular effects) affect athletic performance negatively. The conversation with the prescribing clinician about competitive considerations matters.
Some athletes choose to take medication only during the school year and not during competitive seasons. This is a clinical decision with the family and clinician, not a choice for performance reasons primarily.
The non-medication alternatives.
For some kids with ADHD, non-medication approaches are part of the treatment. The published evidence:
Behavioral therapy and parent-training in behavior management have evidence for younger kids.
Academic accommodations under 504 plans or Individualized Education Programs (IEPs) for school settings.
Lifestyle factors (sleep, exercise, nutrition, screen time management) have modest evidence for symptom management.
Some families choose to manage ADHD without medication for competitive seasons specifically. The clinical decision matters; it should be made with the clinician, not for anti-doping reasons alone.
The non-stimulant medication option.
Some ADHD medications are non-stimulants and may not be on the banned list (Strattera/atomoxetine, guanfacine, clonidine).
These are sometimes used as alternatives for athletes who:
Cannot take stimulants for medical reasons.
Have not had TUE approval.
Want to avoid the testing-related complications.
The clinical decision about non-stimulant medication is appropriate to discuss with the prescribing clinician. For some kids, non-stimulants work well. For others, stimulants are clinically necessary.
For coaches.
A program-level awareness of TUE requirements for athletes on banned medications.
Communication with the school athletic department or compliance office about athletes’ prescription needs.
Refraining from advising athletes to start or stop medications for athletic reasons. The clinical decision belongs to the family and the prescribing clinician.
For families.
The TUE process is not optional for the kid on ADHD medication who is going to be tested.
The documentation in advance protects the kid from a positive test result with no paperwork.
The clinical decision about medication remains a family-and-clinician decision. The anti-doping framework is administrative, not clinical.
The honest read. ADHD medication and competitive sport intersect in a way most families do not encounter until the testing arrives. The TUE process protects athletes with legitimate medical needs. The kids whose families understand and complete the process before testing are kids whose competitive eligibility is preserved.
For families with ADHD-diagnosed kids on the recruiting track, the conversation with the prescribing clinician about TUE planning matters as much as the recruiting conversation.